Sentinel node biopsy in melanoma: Still recommended in 2025?

In this episode of Melanoma Insights for Professionals, we explore the evolving role of sentinel node biopsy (SNB) in melanoma management—particularly in the modern context of perioperative drug therapy.

Our expert panel unpacks current evidence, shifting guidelines and real-world clinical considerations influencing when and why SNB is performed. Topics include prognostic value, surgical decision-making, pathological assessment, patient-centred perspectives and the impact of new treatment approaches on traditional staging practices.

This podcast is produced by Melanoma Institute Australia and is suitable for multidisciplinary specialists, primary care physicians and other healthcare professionals.

RESOURCES:

• Melanoma Risk Prediction Tools
• Patient brochure on SNB
• MIA's Melanoma Education Portal (Clinicians only)

SPEAKERS:

• A/Prof Alexander van Akkooi - Associate Professor in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal Prince Alfred Hospital, The University of Sydney
• A/Prof Robyn Saw - Surgical Oncologist, Melanoma Institute Australia | Head of Department in Melanoma and Surgical Oncology, Royal Prince Alfred Hospital | Associate Professor in Surgery, The University of Sydney
• A/Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney
• Dr Robert Rawson - Pathologist, Melanoma Institute Australia |Tissue Pathology Staff Specialist, Royal Prince Alfred Hospital

Please note that this podcast was accurate at the time of recording (May 2025) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

MIA’s Education Program is proudly supported through unrestricted educational grants from Bristol Myers Squibb, MSD and HEINE.